GlassScriptPhysician profile
Dawn E Tingwald
NPI 1083169270
$1,013.80
in general payments reported to CMS, 2019-2025
21 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $360 · 2022: $192 · 2023: $113 · 2024: $174 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $462.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $128.97 | 2024-2025 | Aristada, Aristada Initio, Lybalvi |
| Abbvie INC. | $99.13 | 2021-2025 | |
| Pfizer INC. | $95.62 | 2021-2022 | |
| Amgen INC. | $95.06 | 2021-2025 | Krystexxa |
| Janssen Pharmaceuticals, INC | $77.15 | 2021 | |
| Novo Nordisk INC | $66.12 | 2021-2025 | Wegovy |
| Insulet Corporation | $56.92 | 2023-2025 | Omnipod |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.06 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $43.00 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $40.70 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.17 | 2021-2022 | |
| Abbott Laboratories | $40.12 | 2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $37.80 | 2021 | |
| Neurocrine Biosciences, INC. | $32.32 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.54 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.79 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.13 | 2022 | |
| Mylan Specialty L.P. | $15.48 | 2022 | |
| Astellas Pharma US INC | $14.13 | 2021 | |
| Sunovion Pharmaceuticals INC. | $12.48 | 2022 | |
| Dexcom, INC. | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Tingwald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.